Theralase Successfully Repurposes Non-Cancer Drugs for Cancer Therapy

Toronto-based Theralase Technologies Inc. (TSXV:TLT, OTCQB:TLTFF), a clinical-stage pharmaceutical firm, has announced promising preclinical research on Rutherrin®. Their lead drug formulation has demonstrated the ability to repurpose existing non-cancer drugs for cancer treatment.

Repurposing involves finding new uses for clinically approved drugs, aiming to cut costs, reduce development timelines, and bypass some testing challenges. Notably, Theralase's preclinical results indicate that Rutherrin® can enhance the efficacy of drugs like Withaferin A, Amiodarone, and Metformin in killing cancer cells without needing light or radiation activation.

Chief Scientific Officer Dr. Arkady Mandel highlighted the significance of this approach and its potential to unlock other non-cancer drugs for oncology. Roger DuMoulin-White, CEO, emphasized the cost and time efficiencies in repurposing drugs amidst the lengthy, expensive drug development process.